ESBL E coli and P. aeruginosa Resistance to Ceftolozane-Tazobactam in a Patient with a Liver Abscess. The Search for an Omnipotent Antibiotic Goes On!

Title:ESBL E coli and P. aeruginosa Resistance to Ceftolozane-Tazobactam in a Patient with a Liver Abscess. The Search for an Omnipotent Antibiotic Goes On!

Volume: 18 Issue: 1

Author(s): Mohamed Teleb, Enrique Soto-Ruiz, Delfina C. Dominguez and Suresh Antony*

Affiliation:

• Section of Infectious Diseases, Department of Medicine, Texas Tech University, Texas 79902,United States

Keywords: Ceftolozane/Tazobactam, ESBL, gram negative bacteria, mutation, pseudomonas, resistance.

Abstract: Multi drug resistant (MDR) Pseudomonas aeruginosa and Extended- Spectrum-lactamase (ESBL) Enterobacteriaceae are becoming an increasing difficult clinical problem. Immediate resistance to some of the new antimicrobials such as ceftolozane/tazobactam is unusual and is due to a variety of mechanisms such as hyper-production of inactivating enzymes and gene mutation. In addition, previous antimicrobial administration is a well-recognized risk factor to develop resistance. We present a patient with a liver abscess where the organism was resistant to ceftolozane/tazobactam resulting in a poor clinical outcome.

Cite this article as:

Teleb Mohamed, Soto-Ruiz Enrique, Dominguez C. Delfina and Antony Suresh*, ESBL E coli and P. aeruginosa Resistance to Ceftolozane-Tazobactam in a Patient with a Liver Abscess. The Search for an Omnipotent Antibiotic Goes On!, Infectious Disorders - Drug Targets 2018; 18 (1) . https://dx.doi.org/10.2174/1871526516666160713163238